Premium
Human papillomavirus anogenital disease in HIV‐infected individuals
Author(s) -
ChinHong Peter V.,
Palefsky Joel M.
Publication year - 2005
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/j.1529-8019.2005.05009.x
Subject(s) - medicine , disease , colposcopy , anal cancer , dermatology , hpv infection , sexually transmitted disease , human immunodeficiency virus (hiv) , cancer , immunology , cervical cancer , syphilis
Human papillomavirus (HPV) is one of the most common sexually transmitted infections and a significant cause of anogenital malignancies, precancer lesions, and cutaneous disease. Human immunodeficiency virus (HIV)‐positive individuals have a higher prevalence of HPV infection and HPV‐associated anogenital disease compared to age‐matched HIV‐negative controls. Data suggest that there has been little reduction in HPV‐associated disease since the introduction of highly active antiretroviral therapy (HAART). The authors believe that cervical and anal cancer screening using Pap tests should be offered to all HIV‐positive individuals, but the infrastructure to identify (via colposcopy and high‐resolution anoscopy) and treat precancer lesions must be present. Treatment of HPV‐associated anogenital disease depends on the size, location, and grade of the lesion, whereas a variety of ablative and excisional therapies are available. Prophylactic and therapeutic HPV vaccines are promising as future interventions for disease control in at‐risk populations such as HIV‐infected women and men.